ALEXANDRE DE MATOS SOEIRO

(Fonte: Lattes)
Índice h a partir de 2011
14
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: TATIANA DE CARVALHO ANDREUCI TORRES ×

Resultados de Busca

Agora exibindo 1 - 10 de 21
  • article 0 Citação(ões) na Scopus
    Coxiella Burnetii Endocarditis: Can Positron Emission Tomography be an Alternative to Diagnosis?
    (2022) MIZUTA, Marjorie Hayashida; ROMERO, Cristhian Espinoza; VINTIMILLA, Santiago Castro; LEAL, Tatiana de Carvalho Andreucci Torres; SOARES, Paulo Rogerio; SOEIRO, Alexandre de Matos
  • article 1 Citação(ões) na Scopus
    Upper vena cava syndrome secondary to giant atrial myxoma
    (2018) LONGATTO, Flavia Contreira; SANTOS, Thamires Suellen Alves Pereira; SOARES, Marilia Joaquina de Medeiros; NEGRISOLI, Juliana; LEAL, Tatiana de Carvalho Andreucci Torres; BISELLI, Bruno; OLIVEIRA JR., Mucio Tavares; SOEIRO, Alexandre de Matos
    Cardiac myxoma is a benign neoplasm, which corresponds to the most common primary heart tumour, responsible for about 50% of the cases. In general, 75-80% of myxomas are located in the left atrium, 18% in the right atrium, and more rarely in the ventricles or multicentric. Right atrial myxoma, in particular, can obstruct the tricuspid valve, causing symptoms of right heart failure, peripheral oedema, hepatic congestion, and syncope. Systemic embolization occurs in 30% of cases, by either tumour fragmentation or total tumour detachment. In the present report, we present a case of a symptomatic patient, who showed a large right intra-atrial lesion, with consequent superior vena cava syndrome, and then underwent surgical resection at admission.
  • bookPart
    Dor Torá no Pronto-Socorro
    (2016) SOEIRO, Alexandre de Matos; LEAL, Tatiana de Carvalho Andreuci Torres; OLIVEIRA JR., Múcio Tavares
  • book
    Cardiologia de emergências em fluxogramas
    (2015) SOEIRO, Alexandre de Matos; LEAL, Tatiana de Carvalho Andreucci Torres; OLIVEIRA JR., Múcio Tavares de; KALIL FILHO, Roberto
  • article 3 Citação(ões) na Scopus
    Is There Safety in the Use of Clopidogrel Loading Dose in Patients Over 75 Years of Age with Acute Coronary Syndrome?
    (2019) SOEIRO, Alexandre de Matos; CASALE, Guilherme; LOPES, Maria Antonieta Albanez Albuquerque de Medeiros; GODOY, Lucas Colombo; BOSSA, Aline Siqueira; BISELLI, Bruno; LEAL, Tatiana de Carvalho Andreucci Torres; SOEIRO, Maria Carolina Feres de Almeida; SERRANO JR., Carlos V; OLIVEIRA JR., Múcio Tavares
    Abstract Background: There is limited evidence in the literature regarding the administration of clopidogrel to acute coronary syndrome (ACS) in patients over 75 years of age. Most studies excluded this age group, making the subject controversial due to the increased risk of bleeding in this population. Objective: This is a retrospective, unicentric, and observational study aimed at assessing whether the administration of clopidogrel loading dose increases bleeding rates in patients over 75 years of age. Methods: Patients were divided into two groups: group I: 75 mg of clopidogrel; group II: 300-to 600-mg loading dose of clopidogrel. A total of 174 patients (129 in group I and 45 in group II) were included between May 2010 and May 2015. Statistical analysis: The primary outcome was bleeding (major and/or minor). The secondary outcome was combined events (cardiogenic shock, reinfarction, death, stroke and bleeding). The comparison between groups was performed through Q-square and T-test. The multivariate analysis was performed by logistic regression, being considered significant p < 0.05. Results: Comparisons between groups I and II showed differences in the prevalence of diabetes (46.5% vs. 24.4%, p = 0.01), arterial hypertension (90.7% vs. 75, p = 0.01), dyslipidemia (62% vs. 42.2%, p = 0.021), ST segment elevation (11.6% vs. 26.6%, p = 0.016) and coronary intervention percutaneous (16.5% vs. 62.2%, p < 0.0001), respectively. In the multivariate analysis, significant differences were observed between groups I and II in relation to the occurrence of bleeding (8.5% vs. 20%, OR = 0.173, 95% CI: 0.049 - 0.614, p = 0.007). Conclusion: A loading dose of 300 mg or more of clopidogrel.
  • bookPart
    Obesidade e doença cardiovascular tromboembólica
    (2015) SOEIRO, Alexandre de Matos; GOMES, Fernando Luiz Torres; LEAL, Tatiana de Carvalho Andreuci Torres; SETANI, Karina Tiemi; SAKAMOTO, Erica; SERRANO JR., Carlos V.
  • article 1 Citação(ões) na Scopus
    Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19)-2020
    (2020) SOEIRO, Alexandre de Matos; LEAL, Tatiana de Carvalho Andreucci Torres; PEREIRA, Marcel de Paula; LIMA, Eduardo Gomes; FIGUEIREDO, Ana Cristina Baptista da Silva; PETRIZ, Joao Luiz Fernandes; PRECOMA, Dalton Betolim; SERRANO JR., Carlos Vicente
  • bookPart
    Introdução
    (2022) SOEIRO, Alexandre de Matos; LEAL, Tatiana de Carvalho Andreucci Torres; BISELLI, Bruno; JúNIOR, Carlos Vicente Serrano; KALIL FILHO, Roberto; JúNIOR, Múcio Tavares de Oliveira
  • article 9 Citação(ões) na Scopus
    Is There Any Relationship between TSH Levels and Prognosis in Acute Coronary Syndrome?
    (2018) SOEIRO, Alexandre de Matos; ARAUJO, Victor Arrais; VELLA, Julia Pitombo; BOSSA, Aline Siqueira; BISELLI, Bruno; LEAL, Tatiana de Carvalho Andreucci Torres; SOEIRO, Maria Carolina Feres de Almeida; SERRANO JR., Carlos V.; MUELLER, Christian; OLIVEIRA JUNIOR, Mucio Tavares de
    Background: Some small studies have related higher levels of thyrotropin (TSH) to potentially worse prognosis in acute coronary syndromes. However, this relationship remains uncertain. Objective: To analyze the outcomes of patients with acute coronary syndromes in relation to the value of TSH at admission. Methods: Observational and retrospective study with 505 patients (446 in group I [TSH <= 4 mIU/L] and 59 in group II [TSH > 4 mIU/L]) with acute coronary syndromes between May 2010 and May 2014. We obtained data about comorbidities and the medications used at the hospital. The primary endpoint was in-hospital all-cause death. The secondary endpoint included combined events (death, non-fatal unstable angina or myocardial infarction, cardiogenic shock, bleeding and stroke). Comparisons between groups were made by one-way ANOVA and chi-square test. Multivariate analysis was determined by logistic regression. Analyses were considered significant when p < 0.05. Results: Significant differences between groups I and II were observed regarding the use of enoxaparin (75.2% vs. 57.63%, p = 0.02) and statins (84.08% vs. 71.19%, p < 0.0001), previous stroke (5.83% vs. 15.25%, p = 0.007), combined events (14.80% vs. 27.12%, OR = 3.05, p = 0.004), cardiogenic shock (4.77% vs. 6.05%, OR = 4.77, p = 0.02) and bleeding (12.09% vs. 15.25%, OR = 3.36, p = 0.012). Conclusions: In patients with acute coronary syndromes and TSH > 4 mIU/L at admission, worse prognosis was observed, with higher incidences of in-hospital combined events, cardiogenic shock and bleeding.
  • article 8 Citação(ões) na Scopus
    Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome
    (2016) SOEIRO, Alexandre de Matos; SILVA, Pedro Gabriel Melo de Barros e; ROQUE, Eduardo Alberto de Castro; BOSSA, Aline Siqueira; ZULLINO, Cindel Nogueira; SIMOES, Sheila Aparecida; OKADA, Mariana Yumi; LEAL, Tatiana de Carvalho Andreucci Torres; SOEIRO, Maria Carolina Feres de Almeida; SERRANO JR., Carlos V.; OLIVEIRA JR., Mucio Tavares
    OBJECTIVES: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission (group I) compared to patients who did not use oral beta-blockers in this timeframe (group II). METHODS: This was an observational, retrospective and multicentric study with 2,553 patients (2,212 in group I and 341 in group II). Data regarding demographic characteristics, coronary treatment and medication use in the hospital were obtained. The primary endpoint was in-hospital all-cause mortality. The groups were compared by ANOVA and the chi-square test. Multivariate analysis was conducted by logistic regression and results were considered significant when p < 0.05. RESULTS: Significant differences were observed between the groups in the use of angiotensin-converting enzyme inhibitors, enoxaparin, and statins; creatinine levels; ejection fraction; tabagism; age; and previous coronary artery bypass graft. Significant differences were also observed between the groups in mortality (2.67% vs 9.09%, OR= 0.35, p= 0.02) and major adverse cardiovascular events (11% vs 29.5%, OR= 4.55, p= 0.02). CONCLUSIONS: Patients with acute coronary syndrome who underwent early intervention with oral betablockers during the first 24 hours of hospital admission had a lower in-hospital death rate and experienced fewer major adverse cardiovascular events with no increase in cardiogenic shock or sustained ventricular arrhythmias compared to patients who did not receive oral beta-blockers within this timeframe.